MetaVia (MTVA) Competitors $0.70 +0.01 (+1.78%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MTVA vs. ANL, CLNN, HOWL, GNTA, APLT, IMMX, ABVC, CELU, ALXO, and VTVTShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Adlai Nortye (ANL), Clene (CLNN), Werewolf Therapeutics (HOWL), Genenta Science (GNTA), Applied Therapeutics (APLT), Immix Biopharma (IMMX), ABVC BioPharma (ABVC), Celularity (CELU), ALX Oncology (ALXO), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Adlai Nortye Clene Werewolf Therapeutics Genenta Science Applied Therapeutics Immix Biopharma ABVC BioPharma Celularity ALX Oncology vTv Therapeutics MetaVia (NASDAQ:MTVA) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Which has stronger earnings & valuation, MTVA or ANL? MetaVia has higher earnings, but lower revenue than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/AAdlai Nortye$5M13.21-$51.87MN/AN/A Is MTVA or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -212.00% -107.21% Adlai Nortye N/A N/A N/A Do institutionals and insiders hold more shares of MTVA or ANL? 1.4% of MetaVia shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, MTVA or ANL? MetaVia has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500. Does the media favor MTVA or ANL? In the previous week, Adlai Nortye had 2 more articles in the media than MetaVia. MarketBeat recorded 4 mentions for Adlai Nortye and 2 mentions for MetaVia. Adlai Nortye's average media sentiment score of 1.54 beat MetaVia's score of 0.64 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate MTVA or ANL? MetaVia presently has a consensus price target of $7.50, suggesting a potential upside of 977.74%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 402.79%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts clearly believe MetaVia is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryMetaVia and Adlai Nortye tied by winning 6 of the 12 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.84M$3.15B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.4375.4026.02Price / SalesN/A419.38514.85113.09Price / CashN/A44.4425.8129.91Price / Book0.769.6112.166.25Net Income-$27.59M-$53.29M$3.29B$270.76M7 Day Performance0.87%0.13%0.74%3.87%1 Month Performance8.73%5.55%5.00%5.49%1 Year PerformanceN/A10.44%62.55%25.86% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.5625 of 5 stars$0.70+1.8%$7.50+977.7%N/A$16.84MN/A0.008Gap UpANLAdlai Nortye1.9815 of 5 stars$1.77+2.9%$9.00+408.5%-21.8%$65.31MN/A0.00127News CoveragePositive NewsShort Interest ↓CLNNClene3.162 of 5 stars$6.47-2.0%$32.60+403.9%-13.9%$64.89M$286K-1.72100News CoverageAnalyst ForecastHOWLWerewolf Therapeutics3.8602 of 5 stars$1.41+2.9%$8.00+467.4%-38.9%$64.48M$1.88M-0.8640GNTAGenenta Science2.7659 of 5 stars$3.50+2.3%$25.00+614.3%-24.4%$64.02MN/A0.007APLTApplied Therapeutics4.0454 of 5 stars$0.44+1.0%$6.10+1,272.3%-91.4%$64.01M$121K-0.9930Positive NewsGap DownIMMXImmix Biopharma2.9519 of 5 stars$2.19-3.9%$7.00+219.6%+12.3%$63.14MN/A-2.849News CoverageAnalyst ForecastShort Interest ↑ABVCABVC BioPharma0.6876 of 5 stars$2.68-2.5%N/A+310.6%$63.09M$391.24K-15.7630CELUCelularity1.7009 of 5 stars$2.35+4.0%$6.00+155.3%-16.7%$62.72M$54.22M-0.74220Analyst UpgradeALXOALX Oncology3.5413 of 5 stars$1.17+7.3%$3.30+182.1%-52.3%$62.66MN/A-0.5340News CoverageVTVTvTv Therapeutics2.6171 of 5 stars$19.57+4.2%$35.50+81.4%+39.1%$62.51M$17K-6.279Gap Up Related Companies and Tools Related Companies ANL Alternatives CLNN Alternatives HOWL Alternatives GNTA Alternatives APLT Alternatives IMMX Alternatives ABVC Alternatives CELU Alternatives ALXO Alternatives VTVT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTVA Stock Alerts